Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of LY2605541 versus human insulin NPH as basal insulin in insulin-naïve type 2 diabetes
2012-003941-13Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2013
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin peglispro in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in HbA1c from baseline to 26 weeks. Started Jan 2013; status: completed.
02
Drugs
insulin peglispro
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-003941-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003941-13.